Meletios A. Dimopoulos, MD, is an a professor and chairman in the Department of Clinical Therapeutics at the National and Kapodistrian University of Athens School of Medicine

Dr Dimopoulos on Elranatamab Plus Daratumumab and Lenalidomide in Myeloma

Meletios A. Dimopoulos, MD, a professor and chairman in the Department of Clinical Therapeutics at the National and Kapodistrian University of Athens School of Medicine, discussed efficacy and safety findings from part 1 of the MagnetisMM-6 trial (NCT05623020), which is investigating elranatamab-bcmm (Elrexfio) plus daratumumab (Darzalex) and lenalidomide (Revlimid) in patients with newly diagnosed multiple myeloma.

OncLive TV

® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers. 

Conference

® Conference page includes a listing of all conferences covered by 

, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.


Multiple Myeloma

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

European Hematology Association Congress

Meletios A. Dimopoulos, MD, discusses efficacy and safety findings with elranatamab plus daratumumab and lenalidomide in newly diagnosed multiple myeloma.